3PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.
3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO) with locations in Pamplona (Spain) and Turku (Finland), has been awarded the prestigious CDMO Leadership Award 2025 in the “Cell & Gene Therapy International” category. This award recognizes the excellence of the services that 3PBIOVIAN provides to the Advanced Therapies industry, solidifying its position as a leader in the international sector.
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
3PBIOVIAN